Epigenomics raises EUR 33,1 million
Berlin - On March 30th, Berlin-based biomarker specialist Epigenomics, successfully raised EUR 33,1 million at the public market through the placement of 14,697,361 new shares. The offering started on March 15 at a subscription price of EUR 2.25 per new share and all existing shareholders could buy one new share for every two shares they owned. 46.2% equalling 6,789,613 new shares were sold this way. The remaining 7,907,748 unsubscribed new shares were sold at the subscription price to retail investors as part of a public offering in Germany and Austria, as well as to selected institutional investors in Germany and abroad. London based Abingworth LLP utilised this to become the biggest shareholder of Epigenomics after the capital increase. Epigenomics AG intends to use a significant portion of the net proceeds from the offering to commercialise the septin9-biomarker for the diagnosis of colorectal cancer and develop it further for the use as a diagnostic tool for lung cancer.